Alkermes plc (NASDAQ:ALKS) today announced the presentation of research related to its psychiatry portfolio—which includes LYBALVI® (olanzapine and samidorphan) and ARISTADA® (aripiprazole lauroxil)—at four scientific conferences this spring. Several of these meetings coincide with Mental Health Awareness Month in May, an important moment in the year that provides an opportunity to raise awareness about mental health conditions, support the millions of people living with these complex diseases, and acknowledge the critical work of healthcare providers who deliver care each day. The meetings include:
- Schizophrenia International Research Society (SIRS) Annual Congress, May 11-15, Toronto
- American Psychiatric Association (APA) Annual Meeting, May 20-24, San Francisco
- American Society of Clinical Psychopharmacology (ASCP) Annual Meeting, May 30-June 2, Miami
- The International Society for Bipolar Disorders (ISBD) Annual Conference, June 22-25, Chicago
